Clinical significance of the haemopoietic growth factors

Devereux, S; Linch, DC

doi:10.1038/bjc.1989.2

Cited by 16 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent advances in the immunobiological knowledge have resulted in the availability of specific growth factors for the single hematopoietic cell lines, i.e. erythropoietin for red cells and granulocyte-(G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for neutrophils (2). Lymphocytes also have their growth factors, the most important of which being interleukin-2 (IL-2) (3), particularly for T lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

Changes in Lymphocyte Number during Cancer Chemotherapy and Their Relation to Clinical Response

et al. 1999

View full text Add to dashboard Cite

Since hematologic examination during cancer chemotherapy is generally limited to the evaluation of neutrophil and platelet numbers, at present there are no clear data about the possible prognostic significance of changes in lymphocyte number in relation to the clinical efficacy of chemotherapy itself. To obtain some preliminary data about this issue, we have evaluated changes in lymphocyte number and percentage in a group of 50 advanced non-small cell lung cancer patients treated with three cycles of cisplatin (20 mg/m2/day) plus etoposide (100 mg/m2/day) i.v. for three days every 21 days. The clinical response consisted of partial response (PR) in nine (18%), stable disease (SD) in 18 (36%) and progressive disease (PD) in the remaining 23 (46%) patients. The lymphocyte percentage increased during chemotherapy, without, however, a significant difference with respect to the pretreatment values. In contrast, the mean number of lymphocytes observed after the first chemotherapeutic cycle significantly decreased in patients with PD, whereas it increased in patients with PR or SD, even though the difference did not reach statistical significance. These preliminary data, which have to be confirmed in a large number of patients and in patients treated with other chemotherapeutic schedules for different tumor types, seem to suggest that a chemotherapy-induced decline in lymphocyte number may be associated with a lack of efficacy of chemotherapy itself.

show abstract

Section: Introductionmentioning

confidence: 99%

Changes in Lymphocyte Number during Cancer Chemotherapy and Their Relation to Clinical Response

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Dazu zählen vor allem die Zellvermehrung in Knochenmark und Blut [8, 9, 10, 11, 12, 13. 14, 15] und die Aktivierung reifer funktionsfähiger Granulozyten und Monozyten [7,16,17,18,19,20]. Onkologisch bedeutsam sind differenzierte Wirkungen des GM-CSF wie die Induktion der ADCC [13,21] …”

Section: Introductionunclassified

Steigerung der Zytotoxizität spezifischer monoklonalen Antikörper gegen humane Karzinomzellen durch GM-CSF in vitro

Staib¹,

Link²,

Büchler³

1991

Oncol Res Treat

View full text Add to dashboard Cite

In einem 4-h-Cr51-Release-Assay wurde die antikörpervermittelte Zytotoxizität (ADCC) humaner peripherer, mononukleärer Blutzel- len (je Ansatz 10⁶ Zellen) mit und ohne Zusatz von «Granulocyte- Macrophage Colony Stimulating Factor» (= GM-CSF, je Ansatz 0,1 μg) gegenüber den humanen Karzinomzellinien (10⁴ Zellen pro Ansatz) PaTu II (Pankreas), LoVo (Kolon) und M21 (Melanom) untersucht. Als spezifische monoklonale Antikörper wurden BW 494/32 IgGl und 2a sowie BW 495/33 (gegen Kolon- und Pankreasmuzin) sowie BW 599/4 (gegen Melanom-Gangliosid) verwendet. Die Spezifität der Antikörper BW 494/32 und 599/4 wurde mit fluoreszingebundenen Antikörpern (FACS-Analyse) belegt. Die jeweils höchste erzielbare ADCC betrug fur PaTu II 36 ± 6,0% (x ± sem, n = 6) mit BW 494/32 IgGl, für LoVo 45 + 6,8% mit BW 494/32 IgG2a und für M21 27 ± 3,5% mit BW 599/4 IgG3. Wurde mit GM-CSF zwei Stunden lang vorinkubiert, stieg die ADCC in alien Gruppen signifikant (p < OOl): PaTu II 78 ± 8,7%, LoVo 85 ± 6,8% undM21 74 ± 4,7%. Diese Befunde könnten in der additiven Behandlung von Patienten mit Pankreaskarzinom, Kolonkarzinom oder Melanom einen immun- biologischen Therapieansatz rechtfertigen.

show abstract

The role of hematopoietic growth factors in small cell lung cancer: a review

Trillet‐Lenoir

1994

Cancer Treatment and Research

View full text Add to dashboard Cite

Clinical significance of the haemopoietic growth factors

Cited by 16 publications

References 28 publications

Changes in Lymphocyte Number during Cancer Chemotherapy and Their Relation to Clinical Response

Changes in Lymphocyte Number during Cancer Chemotherapy and Their Relation to Clinical Response

Steigerung der Zytotoxizität spezifischer monoklonalen Antikörper gegen humane Karzinomzellen durch GM-CSF in vitro

The role of hematopoietic growth factors in small cell lung cancer: a review

Contact Info

Product

Resources

About